Translational imaging in toxicology

IF 4.6

Current opinion in toxicology Pub Date : 2020-10-01 DOI:10.1016/j.cotox.2020.03.006

Serguei Liachenko

{"title":"Translational imaging in toxicology","authors":"Serguei Liachenko","doi":"10.1016/j.cotox.2020.03.006","DOIUrl":null,"url":null,"abstract":"<div>In vivo imaging has a potential to bring innovation to translational toxicology for drug discovery. This includes magnetic resonance imaging, positron emission tomography (PET), single photon emission tomography, and computed tomography. The utility of imaging comes from its capacity to provide minimally invasive biomarkers for safety profiling and decision-making in drug discovery. Nonspecific biomarkers, such as magnetic resonance imaging relaxometry, computed tomography density, or PET 18F-fluoro-2-deoxy-d-glucose are better suited for preclinical general toxicology and clinical monitoring, while specific ones, such as most of PET and single photon emission tomography ligands, are better suited to clarify mechanisms of toxicity or unwanted target engagement. However, the use of these biomarkers is sporadic and governed by scientific interest and availability rather than its utility. A systematic approach is needed to qualify these biomarkers with regulatory authorities so translational imaging could be incorporated into drug development and its unique potential translated into safer and cheaper medicines.</div>","PeriodicalId":93968,"journal":{"name":"Current opinion in toxicology","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cotox.2020.03.006","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in toxicology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S246820202030022X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

In vivo imaging has a potential to bring innovation to translational toxicology for drug discovery. This includes magnetic resonance imaging, positron emission tomography (PET), single photon emission tomography, and computed tomography. The utility of imaging comes from its capacity to provide minimally invasive biomarkers for safety profiling and decision-making in drug discovery. Nonspecific biomarkers, such as magnetic resonance imaging relaxometry, computed tomography density, or PET ¹⁸F-fluoro-2-deoxy-d-glucose are better suited for preclinical general toxicology and clinical monitoring, while specific ones, such as most of PET and single photon emission tomography ligands, are better suited to clarify mechanisms of toxicity or unwanted target engagement. However, the use of these biomarkers is sporadic and governed by scientific interest and availability rather than its utility. A systematic approach is needed to qualify these biomarkers with regulatory authorities so translational imaging could be incorporated into drug development and its unique potential translated into safer and cheaper medicines.

查看原文本刊更多论文

毒理学中的翻译成像

体内成像有可能为药物发现的转化毒理学带来创新。这包括磁共振成像、正电子发射断层扫描(PET)、单光子发射断层扫描和计算机断层扫描。成像的效用来自于它为药物发现的安全性分析和决策提供微创生物标志物的能力。非特异性生物标志物，如磁共振成像松弛测量、计算机断层扫描密度或PET 18f -氟-2-脱氧-d-葡萄糖更适合于临床前一般毒理学和临床监测，而特异性生物标志物，如大多数PET和单光子发射断层扫描配体，更适合于阐明毒性机制或不想要的靶标接触。然而，这些生物标志物的使用是零星的，受科学兴趣和可用性的支配，而不是其效用。需要一种系统的方法使这些生物标记物获得监管机构的认可，以便将转化成像纳入药物开发，并将其独特的潜力转化为更安全、更便宜的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in toxicology Toxicology, Biochemistry

CiteScore

8.50

自引率

0.00%

发文量

审稿时长

64 days